BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Michael Rice Sells 16,666 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Michael Rice sold 16,666 shares of BioLife Solutions stock in a transaction on Monday, January 10th. The shares were sold at an average price of $30.83, for a total transaction of $513,812.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Rice also recently made the following trade(s):

  • On Wednesday, January 12th, Michael Rice sold 16,666 shares of BioLife Solutions stock. The stock was sold at an average price of $31.72, for a total transaction of $528,645.52.
  • On Wednesday, December 29th, Michael Rice sold 928 shares of BioLife Solutions stock. The stock was sold at an average price of $39.37, for a total transaction of $36,535.36.
  • On Monday, December 13th, Michael Rice sold 16,666 shares of BioLife Solutions stock. The stock was sold at an average price of $33.82, for a total transaction of $563,644.12.
  • On Wednesday, December 15th, Michael Rice sold 16,666 shares of BioLife Solutions stock. The stock was sold at an average price of $32.80, for a total transaction of $546,644.80.
  • On Thursday, December 9th, Michael Rice sold 11,464 shares of BioLife Solutions stock. The stock was sold at an average price of $35.15, for a total transaction of $402,959.60.
  • On Tuesday, December 7th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The stock was sold at an average price of $36.52, for a total transaction of $418,555.72.
  • On Tuesday, November 2nd, Michael Rice sold 11,461 shares of BioLife Solutions stock. The stock was sold at an average price of $54.72, for a total value of $627,145.92.
  • On Thursday, November 4th, Michael Rice sold 11,461 shares of BioLife Solutions stock. The stock was sold at an average price of $56.81, for a total value of $651,099.41.
  • On Thursday, October 14th, Michael Rice sold 3,215 shares of BioLife Solutions stock. The stock was sold at an average price of $39.97, for a total value of $128,503.55.

Shares of BLFS opened at $30.84 on Friday. The firm has a market cap of $1.26 billion, a P/E ratio of 308.43, a price-to-earnings-growth ratio of 19.96 and a beta of 1.61. BioLife Solutions, Inc. has a 12-month low of $28.15 and a 12-month high of $60.67. The company’s 50-day moving average price is $39.64 and its 200 day moving average price is $44.56. The company has a current ratio of 3.65, a quick ratio of 2.82 and a debt-to-equity ratio of 0.01.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, November 11th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.21). The business had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.65 million. BioLife Solutions had a negative return on equity of 2.39% and a net margin of 4.87%. During the same quarter last year, the company earned ($0.02) earnings per share. Equities research analysts forecast that BioLife Solutions, Inc. will post -0.28 earnings per share for the current year.

Several research firms have recently commented on BLFS. Zacks Investment Research upgraded BioLife Solutions from a “sell” rating to a “hold” rating in a report on Wednesday. Maxim Group started coverage on BioLife Solutions in a report on Friday, November 12th. They set a “buy” rating and a $60.00 price target on the stock. Finally, B. Riley restated a “buy” rating on shares of BioLife Solutions in a report on Thursday, November 11th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $59.13.

Large investors have recently modified their holdings of the business. Macquarie Group Ltd. purchased a new stake in BioLife Solutions during the second quarter worth about $26,000. Nisa Investment Advisors LLC purchased a new stake in BioLife Solutions during the second quarter worth about $29,000. Center for Financial Planning Inc. purchased a new stake in BioLife Solutions during the third quarter worth about $57,000. Citigroup Inc. increased its stake in BioLife Solutions by 25.1% during the second quarter. Citigroup Inc. now owns 1,643 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 330 shares during the period. Finally, Royal Bank of Canada increased its stake in BioLife Solutions by 113.8% during the second quarter. Royal Bank of Canada now owns 1,672 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 890 shares during the period. Institutional investors own 85.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

Read More: What is a bull market?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.